With with GLP-1 drugs, gastrointestinal issues, such as nausea, vomiting, constipation, and gastroesophageal reflux disease, are among the most common adverse effects.

As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has uncovered neurological and behavioral health benefits amid risks for pancreatitis and kidney disease.

The benefits of taking GLP-1 agonists seem to outweigh the risks, at least when taken for approved uses, according to an assessment of how the drugs affect 175 conditions

A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, addiction, heart disease, and gastrointestinal problems, among others.

Early research suggests GLP-1 drugs could prevent or treat Alzheimer's Disease. Results from a big clinical trial could soon confirm that.

Novo Nordisk ( NYSE:NVO) and Eli Lilly ( NYSE:LLY) are making headlines againthis time, for potential benefits beyond weight loss. A new study finds that people taking GLP-1 medications like Ozempic, Wegovy, and Mounjaro face up to a 12% lower risk of developing Alzheimer's disease.

In all, researchers found that people taking GLP-1 medications had lower risks for 42 health outcomes, including liver failure, lung failure, cardiac arrest, aspiration pneumonia and shock.

In today’s health headlines, the 175 health benefits and risks of taking GLP-1 drugs. Also, many older adults don’t realize they meet the criteria for a dementia diagnosis. Finally, what are the brain effects of short video watching on TikTok and reels?

The stock price of the two most prominent players in the diabetes and obesity care market, Novo Nordisk NVO and Eli Lilly LLY, rose 3% and 2.3% on Tuesday, respectively, after results from a study showed that GLP-1 drugs cut the risk of several heart conditions,